Mode
Home
Conditions Medications Drug Pipeline Weekly Digests
Text Size
Log in / Sign up
Home › Conditions › Merkel Cell Carcinoma

Merkel Cell Carcinoma

2 published articles · Updated continuously

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
PD-L1 expression shows subtype-specific prognostic value in skin neoplasms, meta-analysis finds
Dermatology Meta-analysis
PD-L1 expression shows subtype-specific prognostic value in skin neoplasms, meta-analysis finds Does a common cancer marker predict survival in skin cancers? It depends.
A meta-analysis of 24 observational studies found PD-L1 expression was not significantly associated with overall survival (HR=0.89, 95% CI: …
A common skin cancer marker doesn't predict survival for everyone, but it does for specific types like Merkel cell carcinoma and melanoma.
Apr 6, 2026
FDA Approves Zynyz (retifanlimab-dlwr) for Metastatic Anal Canal Cancer and Merkel Cell Carcinoma
Oncology FDA Approval
FDA Approves Zynyz (retifanlimab-dlwr) for Metastatic Anal Canal Cancer and Merkel Cell Carcinoma FDA approves new drug Zynyz for two rare and aggressive types of cancer.
The FDA has approved Zynyz, a PD-1 blocking antibody, for two indications: first-line treatment of inoperable locally recurrent or metastati…
FDA approves new drug Zynyz to treat two rare and aggressive cancers: advanced anal cancer and Merkel cell carcinoma.
FDA Apr 2, 2026